| 前收盘价格 | 1.29 |
| 收盘价格 | 1.30 |
| 成交量 | 11,234,045 |
| 平均成交量 (3个月) | 3,462,269 |
| 市值 | 1,023,038,336 |
| 价格/销量 (P/S) | 1.28 |
| 股市价格/股市净资产 (P/B) | 0.660 |
| 52周波幅 | |
| 利润日期 | 5 Aug 2025 - 11 Aug 2025 |
| 营业毛利率 | -5.66% |
| 营业利益率 (TTM) | -44.79% |
| 稀释每股收益 (EPS TTM) | -0.060 |
| 季度收入增长率 (YOY) | -13.70% |
| 总债务/股东权益 (D/E MRQ) | 37.58% |
| 流动比率 (MRQ) | 2.49 |
| 营业现金流 (OCF TTM) | -182.48 M |
| 杠杆自由现金流 (LFCF TTM) | -107.74 M |
| 资产报酬率 (ROA TTM) | -8.20% |
| 股东权益报酬率 (ROE TTM) | -3.04% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 看跌 | 看跌 |
| Diagnostics & Research (全球的) | 看跌 | 看跌 | |
| 股票 | Opko Health, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
1.4
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.38 |
|
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Value |
| 内部持股比例 | 46.81% |
| 机构持股比例 | 31.12% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 3.00 (HC Wainwright & Co., 132.56%) | 购买 |
| 中 | 2.63 (103.88%) | |
| 低 | 2.25 (Barrington Research, 74.42%) | 购买 |
| 平均值 | 2.63 (103.88%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 1.44 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Barrington Research | 01 May 2025 | 2.25 (74.42%) | 购买 | 1.35 |
| HC Wainwright & Co. | 07 Apr 2025 | 3.00 (132.56%) | 购买 | 1.53 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合